Last reviewed · How we verify

Meglumine antimoniate

University of Brasilia · FDA-approved active Small molecule ✓ Verified May 2026 Quality 6/100

Meglumine antimoniate is a Small molecule drug developed by University of Brasilia. It is currently FDA-approved. Also known as: Glucantime, High dose, Low dose, Glucantime®.

Meglumine antimoniate is a small molecule medicine used to treat leishmaniasis, including cutaneous leishmaniasis. It is administered by injection into a muscle or the infected area.

At a glance

Generic nameMeglumine antimoniate
Also known asGlucantime, High dose, Low dose, Glucantime®, glucantime
SponsorUniversity of Brasilia
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Meglumine antimoniate

What is Meglumine antimoniate?

Meglumine antimoniate is a Small molecule drug developed by University of Brasilia.

Who makes Meglumine antimoniate?

Meglumine antimoniate is developed and marketed by University of Brasilia (see full University of Brasilia pipeline at /company/university-of-brasilia).

Is Meglumine antimoniate also known as anything else?

Meglumine antimoniate is also known as Glucantime, High dose, Low dose, Glucantime®, glucantime.

What development phase is Meglumine antimoniate in?

Meglumine antimoniate is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing